Exencial Wealth Advisors LLC Has $6.95 Million Stock Holdings in The Cooper Companies, Inc. $COO

Exencial Wealth Advisors LLC decreased its stake in The Cooper Companies, Inc. (NASDAQ:COO) by 4.4% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 97,671 shares of the medical device company’s stock after selling 4,516 shares during the period. Exencial Wealth Advisors LLC’s holdings in Cooper Companies were worth $6,950,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also added to or reduced their stakes in COO. Exchange Traded Concepts LLC grew its stake in Cooper Companies by 16.3% during the first quarter. Exchange Traded Concepts LLC now owns 1,502 shares of the medical device company’s stock worth $127,000 after purchasing an additional 210 shares during the period. State of Alaska Department of Revenue grew its stake in Cooper Companies by 3.0% during the first quarter. State of Alaska Department of Revenue now owns 23,390 shares of the medical device company’s stock worth $1,972,000 after purchasing an additional 680 shares during the period. Kentucky Retirement Systems Insurance Trust Fund acquired a new stake in Cooper Companies during the first quarter worth approximately $479,000. Asset Management One Co. Ltd. grew its stake in Cooper Companies by 15.2% during the first quarter. Asset Management One Co. Ltd. now owns 85,567 shares of the medical device company’s stock worth $7,218,000 after purchasing an additional 11,320 shares during the period. Finally, Lecap Asset Management Ltd. grew its stake in Cooper Companies by 72.8% during the first quarter. Lecap Asset Management Ltd. now owns 20,662 shares of the medical device company’s stock worth $1,743,000 after purchasing an additional 8,707 shares during the period. Institutional investors and hedge funds own 24.39% of the company’s stock.

Insider Transactions at Cooper Companies

In related news, COO Daniel G. Mcbride acquired 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 2nd. The shares were bought at an average cost of $65.04 per share, for a total transaction of $195,120.00. Following the purchase, the chief operating officer owned 63,120 shares in the company, valued at $4,105,324.80. This trade represents a 4.99% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Gerard H. Warner III acquired 1,450 shares of the firm’s stock in a transaction that occurred on Friday, September 5th. The shares were bought at an average price of $69.23 per share, for a total transaction of $100,383.50. Following the completion of the purchase, the chief operating officer owned 18,319 shares in the company, valued at $1,268,224.37. This trade represents a 8.60% increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 17,975 shares of company stock valued at $1,216,346. 1.98% of the stock is currently owned by insiders.

Cooper Companies Stock Performance

Shares of Cooper Companies stock opened at $75.00 on Wednesday. The business’s fifty day simple moving average is $69.64 and its 200 day simple moving average is $73.21. The firm has a market capitalization of $14.91 billion, a P/E ratio of 36.95, a price-to-earnings-growth ratio of 1.97 and a beta of 1.02. The Cooper Companies, Inc. has a 12 month low of $61.78 and a 12 month high of $109.04. The company has a current ratio of 2.12, a quick ratio of 1.24 and a debt-to-equity ratio of 0.29.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings results on Wednesday, August 27th. The medical device company reported $1.10 EPS for the quarter, topping analysts’ consensus estimates of $1.07 by $0.03. The business had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.06 billion. Cooper Companies had a return on equity of 9.82% and a net margin of 10.08%.Cooper Companies’s quarterly revenue was up 5.7% compared to the same quarter last year. During the same period last year, the company posted $0.96 earnings per share. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. As a group, analysts anticipate that The Cooper Companies, Inc. will post 3.98 EPS for the current year.

Cooper Companies declared that its Board of Directors has authorized a share repurchase program on Wednesday, September 17th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the medical device company to purchase up to 15.4% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s leadership believes its shares are undervalued.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on COO shares. Morgan Stanley set a $76.00 target price on Cooper Companies and gave the stock an “equal weight” rating in a research note on Thursday, August 28th. BNP Paribas Exane raised Cooper Companies from a “neutral” rating to an “outperform” rating and set a $92.00 price objective for the company in a research note on Tuesday, July 22nd. The Goldman Sachs Group set a $64.00 price objective on Cooper Companies and gave the company a “sell” rating in a research note on Wednesday, October 1st. Wall Street Zen cut Cooper Companies from a “buy” rating to a “hold” rating in a research note on Saturday, July 12th. Finally, BNP Paribas raised Cooper Companies from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $84.77.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.